ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Feb. 17, 2004--Maas BiolAB was granted Cyclosporin Neuroprotection patent number 2194527 by RosPatent, the Russian Patent Office. Russia has a population of 141 million people. This Russian patent joins Maas patents in North America (USA, Canada, Mexico), Europe (Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom), Africa (Ghana, Kenya, Lesotho, Malawi, Sudan, Swaziland, Uganda, Zimbabwe) and the Antipodes (Australia, New Zealand).
Maas BiolAB is a privately held neuropharmaceutical corporation based in Albuquerque, NM, USA developing cyclosporin drugs for the neurodegenerative diseases of Alzheimer's, Parkinson's, Huntington's and amyotrophic lateral sclerosis. NeuroPharma AB is a Maas corporate and research partner developing NeuroSTAT(TM), a proprietary, non-toxic intravenous cyclosporin formula for traumatic brain injury, spinal cord injury and stroke. NeuroPharma AB is located in the Medicon Valley biotechnology center of Sweden, with close ties to the Wallenberg Neuroscience Center, Lund University. For more information please visit www.maasbiolab.com.
Maas BiolAB, LLC 1934 Quail Run Loop NE Albuquerque, NM 87122 USA +1-505-797-1020 tel +1-505-797-1024 fax
NeuroPharma AB Magle Stora Kyrkogata 6 223 50 Lund, Sweden
Maas BiolAB, LLC Marcus Keep M.D., 505-797-1020 or
NeuroPharma AB Greg Batcheller, +46-46-157763
Source: Maas BiolAB